|Number of samples:||63|
|Release date:||Nov 21 2016|
|Last update date:||Nov 28 2018|
|Dataset link||Partially exhausted CD8+ T cells are associated with clinically beneficial response to Teplizumab in new onset type I diabetes (bulk RNA-seq of sorted CD8+ T-cells)|
We performed bulk RNA-seq on 63 sorted CD8+ T-cell samples from 3 responders at visit month 6 (N = 34, 15, 14); we sorted cells with and without EOMES-associated inhibitory receptors (TIGIT, KLRG1); prior to RNA extraction, cells were either unstimulated, stimulated with anti-CD3 and anti-CD28, or stimulated with additional PVR-Fc treatment.